BRIGHT-LIGHT: Studying Red Light Therapy for Severe Short-Sightedness or Short-Sightedness That Worsens Despite Standard Treatment
Key facts
- Who runs it
- Singapore National Eye Centre
- Where
- Singapore2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 40 people, planned
- Starts
- 1 Dec 2026
- Expected to end
- 31 Dec 2031
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Repeated low-level red-light (RLRL) therapy
- Continued existing myopia treatment strategy
- Record updated
- 6 November 2026
Who can take part
- Age
- 8 years to 16 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Aged 8-16 years at enrolment
- Cycloplegic spherical equivalent refraction between -3.00 and -20.00 dioptres
- Astigmatism ≤6.00 dioptres
- Documented poor response to conventional myopia-control treatment, defined as axial elongation ≥0.30 mm/year or myopia progression ≥0.50 dioptres/year in at least one eye despite treatment
- Best-corrected visual acuity of 6/9 or better in both eyes
- Informed consent obtained from a parent or guardian
Who cannot take part
- Not currently receiving any myopia-control treatment
- Contraindication to repeated low-level red-light therapy
- Ocular disease other than refractive error
- Strabismus or a binocular vision disorder
- Systemic disease affecting study participation
- Orthokeratology lens use
- Inability to attend follow-up visits
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 8 and 16 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Some children's short-sightedness (myopia) continues to worsen despite treatments such as atropine eye drops, myopia-control spectacles or contact lenses. These children may be at greater risk of developing severe short-sightedness and related eye problems later in life.
Read full original descriptionShow less
The BRIGHT-LIGHT study will assess the safety of repeated low-level red-light therapy and explore whether it can slow worsening short-sightedness in children whose myopia is inadequately controlled by conventional treatment. This therapy uses a device that delivers low-power red light to the eyes during short treatment sessions.
Forty children aged 8-16 years will be followed for 12 months: 30 receiving red-light therapy and 10 continuing conventional myopia treatment. Group assignment will depend on the willingness of children and their parents or guardians to start red-light therapy, rather than random allocation.
The main focus is safety, assessed through vision tests, detailed eye scans and tests of retinal function. The study will also assess changes in eye length and spectacle prescription to explore the treatment's effect on myopia progression.
The 2 groups in the trial
- Repeated Low-Level Red-Light (RLRL) TherapyTreatment being tested
Participants will receive repeated low-level red-light (RLRL) therapy using the Eyerising Myopia Management Device for 12 months. Each session lasts 3 minutes, with two sessions per treatment day separated by at least 4 hours, up to 10 sessions per week. Participants using myopia-control spectacles or multifocal contact lenses may continue these treatments alongside RLRL or discontinue them and switch to RLRL alone. Participants receiving atropine eye drops must discontinue atropine before starting RLRL.
- Conventional Myopia ManagementExisting treatment, for comparison
Participants will continue conventional myopia-control treatment, such as atropine eye drops, myopia-control spectacles or multifocal contact lenses, without RLRL therapy. This concurrent control group will undergo study assessments over 12 months to allow comparison of safety findings and myopia progression with the RLRL group.
Treatment: Continued existing myopia treatment strategy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Benefit of Repeated Illumination in Group of High Myopes and Treatment-resistant Cases (BRIGHT) - Repeated Low-Level Red Light (RLRL) Therapy (Evaluating RLRL Treatment in High Myopes and Non-Responders to Conventional Myopia Control) (BRIGHT-LIGHT)
- Criteria questions
- Built from NCT07923019, who can take part
- Record updated
- 6 November 2026